BioSpecifics Update

Within the next couple of weeks BioSpecifics can receive very good news if the FDA gives final approval for the marketing of Xiaflex.  Recently, this potential treatment for Dupuytren Contracture without surgery was covered in the prestigious New England Journal of Medicine.  If this drug is approved I would expect a spike in the price of Bio,

Leave a Reply

Your email address will not be published.